Ganesh Aarthi, Shenoy Sundeep, Doshi Viral, Rishi Muhammad, Molnar Janos
Departments of 1Pulmonary and Critical Care and 2Internal Medicine, University of Arizona, Tucson, AZ; 3Department of Sleep Medicine, Oklahoma University, Oklahoma City, OK; 4Department of Critical Care, Mayo Clinic, Rochester, MN; and 5Department of Medicine, Rosalind Franklin University of Medicine and Science, North Chicago, IL.
Am J Ther. 2015 Nov-Dec;22(6):431-4. doi: 10.1097/MJT.0000000000000184.
Noninvasive ventilation (NIV) has been found to be beneficial for respiratory failure in many disease states; however, limited data are available supporting its use in acute asthma exacerbation. A retrospective chart analysis of adult patients admitted for acute asthma exacerbation and treated with NIV between January 2007 and December 2009 at a tertiary care community hospital was done. Ninety-eight patient encounters were identified. Mean age of the patients was 48.3 years, and 46% were male. Nineteen patients failed NIV and required invasive ventilation. There was no significant difference in the mean age, sex, race, and initial blood gas between patients with successful versus failed NIV. Usage of drugs, smoking, and history of past hospital or intensive care unit admission or intubation did not significantly influence the rate of failure of NIV. Patients who needed higher initial FiO2 were more likely to get intubated during their hospital stay (46.2 vs. 20.4%, P = 0.019). Patients who failed NIV were found to have longer duration of hospital stay (6.8 vs. 3.9 days, P= 0.016) and longer intensive care unit stay (4 vs. 0.9 days, P = 0.002). Use of inhalers and other medications was not found to significantly influence the rate of failure of NIV. NIV can be used initially in patients with acute asthma exacerbation, as it is associated with shorter duration of hospital stay and can prevent the morbidity of mechanical intubation. Patients with initial requirement of higher FiO2 were more likely to fail NIV and should be carefully monitored.
无创通气(NIV)已被发现在许多疾病状态下对呼吸衰竭有益;然而,支持其用于急性哮喘加重期的可用数据有限。对2007年1月至2009年12月期间在一家三级社区医院因急性哮喘加重期入院并接受NIV治疗的成年患者进行了回顾性病历分析。共识别出98例患者。患者的平均年龄为48.3岁,46%为男性。19例患者NIV治疗失败,需要有创通气。NIV治疗成功与失败的患者在平均年龄、性别、种族和初始血气方面无显著差异。药物使用、吸烟以及既往住院或重症监护病房入院或插管史对NIV治疗失败率无显著影响。初始需要较高FiO2的患者在住院期间更有可能接受插管(46.2%对20.4%,P = 0.019)。NIV治疗失败的患者住院时间更长(6.8天对3.9天,P = 0.016),重症监护病房停留时间更长(4天对0.9天,P = 0.002)。未发现使用吸入器和其他药物对NIV治疗失败率有显著影响。NIV可最初用于急性哮喘加重期患者,因为它与较短的住院时间相关,并且可以预防机械插管的并发症。初始需要较高FiO2的患者更有可能NIV治疗失败,应仔细监测。